Mortality Following Ventricular Arrhythmia Suppression by Encainide, Flecainide, and Moricizine After Myocardial Infarction: The Original Design Concept of the Cardiac Arrhythmia Suppression Trial (CAST)

JAMA: The Journal of the American Medical Association

Volumn 270, Issue 20, 1993, Pages 2451-2455

  Epstein, Andrew E ^a   Hallstrom, Alfred P ^a   Rogers, William J ^a   Liebson, Philip R ^a   Seals, A Allen ^a   Anderson, Jeffery L ^a   Cohen, Jerome D ^a   Capone, Robert J ^a   Wyse, D George ^a  

^a CAST Coordinating Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENCAINIDE; FLECAINIDE; MORACIZINE;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART ARREST; HEART DEATH; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ENCAINIDE; FEMALE; FLECAINIDE; HUMAN; MALE; MIDDLE AGE; MORICIZINE; MYOCARDIAL INFARCTION; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; VENTRICULAR FUNCTION, LEFT;

EID: 0027487181     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1993.03510200057032     Document Type: Article

References (24)

1. Heart and Stroke Facts. Dallas, Tex: American Heart Association; 1992:11-17.
2. Kannel WB, Thomas HE. Sudden coronary death: the Framingham Study. Ann N Y Acad Sci. 1982; 382:3-21.
3. Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989;117:151-159.
4. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
5. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324: 781-788.
6. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227-233.
7. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol. 1988;61:501-509.
8. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. Am J Cardiol. 1988;61:704-713.
9. Vaughan Williams EM. A classification of antiarrhythmic drug actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129-147.
10. Greene HL, Roden DM, Katz RJ, et al. The Cardiac Arrhythmia Suppression Trial: first CAST I… then CAST-II. J Am Coll Cardiol. 1992;19: 894-898.
11. Clyne CA, Estes MAM, Wang PJ. Moricizine. N Engl J Med. 1992;327:255-260.
12. Kalbfleisch JP, Prentice RL. The Statistical Analysis of Heart Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
13. Wyse DG, Hallstrom A, McBride R, et al. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. J Am Coll Cardiol. 1991;18:20-28.
14. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
15. Epstein AE, Bigger JT, Wyse DG, et al. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol. 1991;18:14-19.
16. Goldstein S, Pawitan Y, Kennedy H, et al. Ventricular arrhythmia suppression predicts survival in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation. 1990;82(suppl III):III-198.
17. Hallstrom AP, Greene HL, Huther ML, and the CAST Investigators. The healthy responder phenomenon in non-randomized clinical trials. Stat Med. 1991;10:1621-1631.
18. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med. 1992;327:987-992.
19. Teo K, Yusuf S, Furberg C. Overview of randomized clinical trials of low-dose amiodarone on mortality in cardiac patients. Circulation. 1992;86 (suppl 1):1-534.
20. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D, Jordi H. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990; 16:1711-1718.
21. Carins JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation. 1991;84:550-557.
22. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol. 1992; 20:1056-1062.
23. Yusef S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;77:335-371.
24. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992; 327:669-677.